Three‐Year Long‐Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice
uHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long-term survival with a 3 year survival rate of approximately 30%, including 35.9% for first-line users.
Authors
- Kazunari Tanaka (ORCID: https://orcid.org/0000-0001-9811-2665)
- Yuki Kanayama (ORCID: https://orcid.org/0000-0002-8639-5212)
- Hidenao Noritake (ORCID: https://orcid.org/0000-0003-3649-5335)
- Hideyuki Tamai (ORCID: https://orcid.org/0000-0003-4511-4573)
- Takuya Nagano (ORCID: https://orcid.org/0000-0003-1043-8033)
- Ei Itobayashi (ORCID: https://orcid.org/0000-0003-0475-2819)
- Hiroko Iijima (ORCID: https://orcid.org/0000-0002-5841-8827)
- Hisashi Kosaka (ORCID: https://orcid.org/0000-0002-2926-9973)
- Yuichi Koshiyama (ORCID: https://orcid.org/0009-0006-1247-1215)
- Fujimasa Tada (ORCID: https://orcid.org/0009-0007-3964-5876)
- Kosuke Matsui (ORCID: https://orcid.org/0000-0002-7274-0177)
- Osamu Yoshida (ORCID: https://orcid.org/0000-0002-5015-0045)
- Hideko Ohama
- Teruki Miyake
- Y. Hiasa
- Taeang Arai
- the RELPEC Group and HCC 48 Group
- Tomomi Okubo
- Masashi Hirooka
- Tomoko Aoki
- Chikara Ogawa
- Toru Ishikawa
- Masanori Atsukawa
- Hiroki Nishikawa
- Yoshiko Nakamura
- Tomomitsu Matono
- Kazuya Kariyama
- Takumi Fukumoto
- Takashi Kumada
- Michitaka Imai
- Masaki Kaibori
- Hironori Tanaka
- Asahiro Morishita
- Koichi Takaguchi
- Joji Tani
- Akemi Tsutsui
- Takeshi Hatanaka
- Kunihiko Tsuji
- Atsushi Hiraoka
- Hidekatsu Kuroda
- Shohei Komatsu
- Yutaka Yata
- Kazuto Tajiri
- Hironori Ochi
- Satoru Kakizaki
- Toshifumi Tada
- Hidenori Toyoda
- Atsushi Naganuma
- Takashi Nishimura
- Kazuhito Kawata
- Masatoshi Kudo
- Takanori Matsuura
- Shinichiro Nakamura
- Kazuhiro Nouso
Institutions
- Hiroshima University (JP)
- Kansai Medical University (JP)
- Iwate Medical University (JP)
- Kagawa University (JP)
- Hamamatsu University School of Medicine (JP)
- Wakayama Rosai Hospital (JP)
- Niigata Cancer Center Hospital (JP)
- Takamatsu Red Cross Hospital (JP)
- Saiseikai Niigata Daini Hospital (JP)
- National Hospital Organization Takasaki Medical Center (JP)
- Matsuyama Red Cross Hospital (JP)
- Ogaki Municipal Hospital (JP)
- Himeji Medical Center (JP)
- Hanwa Memorial Hospital (JP)
- Gunma Saiseikai Maebashi Hospital (JP)
- Himeji Red Cross Hospital (JP)
- Teine Keijinkai Hospital (JP)
- Asahi General Hospital (JP)
- Toyama University Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- Kagawa Prefectural Central Hospital (JP)
- Takarazuka City Hospital (JP)
- Ehime University (JP)
- Gifu Kyoritsu University (JP)
- Kobe University (JP)
- Nippon Medical School (JP)
- Hyogo University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Kindai University (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cam4.71640
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00